Genomics of Drug Sensitivity in Cancer |
Mitomycin-C
|
Synonyms |
Mytozytrex, NSC-26980, MMC, Mitosol, Mitozytrex
|
Targets |
DNA crosslinker
|
Target pathway |
DNA replication
|
PubCHEM ID |
5746
|
Jsmol |
|
Download molecule |
5746
|
PUBCHEM IUPAC INCHI |
InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1
|
Smiles |
O=C1(C(=C(N)C(=O)C4(=C1N2(C(OC)(C3(NC3(C2)))C4COC(=O)N)))C)
|
Cluster number |
149
|
calculated LogS |
-1,378
|
Molecular weight |
334,331
|
calculated LogP |
-1,8035
|
H-Acceptors |
9
|
H-Donors |
3
|
Ro5 violations |
0
|
Druglikeness |
4,4964
|
DrugScore |
0,354013313691915
|
Mutagenic |
low
|
Tumorigenic |
low
|
Reproductive Effective |
high
|
Irritant |
none
|
Fish Toxicity |
High FHMT
|
Fish Toxicity2 |
1,2791
|
Rat Acute Toxicity |
4,0153
|
Acute Oral Toxicity |
I
|
Caco-2 Permeability |
Caco2-
|
Caco-2 Permeability2 |
0,4708
|
P-glycoprotein Substrate |
Substrate
|
P-glycoprotein Inhibitor |
Non-inhibitor
|
P-glycoprotein Inhibitor2 |
Non-inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition |
Weak inhibitor
|
Human Ether-a-go-go-Related Gene Inhibition2 |
Non-inhibitor
|
Tetrahymena Pyriformis Toxicity |
High TPT
|
Tetrahymena Pyriformis Toxicity2 |
0,3732
|
AMES Toxicity |
AMES toxic
|
CYP450 2C9 Substrate |
Non-substrate
|
CYP450 3A4 Substrate |
Substrate
|
CYP450 3A4 Inhibitor |
Non-inhibitor
|
CYP450 2C19 Inhibitor |
Non-inhibitor
|
CYP450 2C9 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Inhibitor |
Non-inhibitor
|
CYP450 1A2 Inhibitor |
Non-inhibitor
|
CYP450 2D6 Substrate |
Non-substrate
|
Biodegradation |
Not ready biodegradable
|
Carcinogenicity (Three-class) |
Non-carcinogens
|
Carcinogens |
Danger
|
Blood-Brain Barrier |
BBB-
|
CYP Inhibitory Promiscuity |
High CYP Inhibitory Promiscuity
|
Honey Bee Toxicity |
High HBT
|
Renal Organic Cation Transporter |
Non-inhibitor
|
Subcellular localization |
Mitochondria
|
Human Intestinal Absorption |
HIA+
|
Aqueous solubility |
-2,6819
|